RxDoctor Payments Data

Priya Kumar, MD

Internal Medicine · Bloomington, INNPI 1922003797

Payments from drug & device makers

$518in general payments, 2019–2025

Across 13 payments — averaging $39.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$131
  • Inspire Medical Systems, Inc.$123
  • Amarin Pharma, Inc.$114
  • AstraZeneca$104
  • Exact Sciences$34
  • Teleflex LLC$12

What the payments were for

  • Food & beverage$48293%
  • Education$357%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$518 in reported general payments places this provider in the 65th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$193,086
Medicare patients
478
Services billed
1,972

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide125$165,339
OzempicSemaglutide89$106,185
JardianceEmpagliflozin75$74,025
EliquisApixaban28$39,343
TrulicityDulaglutide25$38,768
JanuviaSitagliptin Phosphate21$30,627
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$25,812
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$8,613
Atorvastatin Calcium777$8,188
ShingrixVaricella-Zoster Ge/As01b/Pf32$6,990
Omeprazole352$5,033
Levothyroxine Sodium546$4,964
PremarinEstrogens, Conjugated15$4,682
SymbicortBudesonide/Formoterol Fumarate20$4,598
Montelukast Sodium287$3,867

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSymbicort$104$4,59820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Bloomington

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →